Objective The effect of CA125, neutrophil to lymphocyte ratio (NLR) and thrombocytosis on
survival has been studied in ovarian cancer. This study explores the link between these …

Highlights • Platinum-based chemotherapy remains the most active treatment for ovarian
cancer. • Platinum should not be withheld after response to last platinum and a treatment-free …

The immunogenicity of malignant cells has recently been acknowledged as a critical
determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory …

The presence of tumor infiltrating lymphocytes (TILs) is associated with a longer overall
survival in advanced stage epithelial ovarian cancer. Despite the prognostic impact of TILs, …

Background/Aim: The presence of ascites in ovarian cancer patients is considered a negative
prognostic factor. The underlying mechanisms are not clearly understood. Materials and …

In the early 2000s a two-tier grading system was introduced for serous ovarian cancer.
Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (…

Background The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and
overall survival (OS) in homologous recombination deficient (HRD) positive patients treated …

Neoplastic cells can escape immune control leading to cancer growth. Regulatory T cells (Treg),
myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) …

Background Tumors can influence peripheral immune macroenvironment, thereby creating
opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and …

Objectives: The phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644) evaluated first-line
standard therapy including bevacizumab in advanced ovarian cancer with the addition of …